NCT05869682
- Conditions
- Advanced Prostate Carcinoma, Genital Diseases, Genital Diseases, Male, +12 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
Clinical trial condition
Stage IV Prostate Cancer AJCC v8
Explore clinical trials studying Stage IV Prostate Cancer AJCC v8. Study availability and eligibility vary by location and protocol.
39 public trials
13 recruiting studies
Stage IV Prostate Cancer AJCC v8 trial results
NCT03678025
- Conditions
- Castration Levels of Testosterone, Genital Diseases, Genital Diseases, Male, +12 more
- Locations
-
- Banner MD Anderson Cancer Center Gilbert, Arizona, United States
- Cancer Center at Saint Joseph's Phoenix, Arizona, United States
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
NCT05054296
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Genital Diseases, Genital Diseases, Male, +12 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Not yet recruiting
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
NCT06129851
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +10 more
- Locations
-
- University of Kansas Cancer Center Kansas City, Kansas, United States
Active, not recruiting
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
NCT05241860
- Conditions
- Castration-Sensitive Prostate Carcinoma, Genital Diseases, Genital Diseases, Male, +9 more
- Locations
-
- Cancer Center at Saint Joseph's Phoenix, Arizona, United States
- Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
- CARTI Cancer Center Little Rock, Arkansas, United States
- Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California, United States
Active, not recruiting
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT06205316
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Genital Diseases, Genital Diseases, Male, +14 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic Health System in Albert Lea Albert Lea, Minnesota, United States
- Mayo Clinic Health System - Mankato Mankato, Minnesota, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Active, not recruiting
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
NCT04592237
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Genital Diseases, +13 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, not recruiting
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT04550494
- Conditions
- Adnexal Diseases, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, +64 more
- Locations
-
- UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States
Active, not recruiting
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT03517969
- Conditions
- Castration-Resistant Prostate Carcinoma, Genital Diseases, Genital Diseases, Male, +10 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- UC San Diego Moores Cancer Center La Jolla, California, United States
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
Active, not recruiting
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT04471974
- Conditions
- Castration-Resistant Prostate Carcinoma, Genital Diseases, Genital Diseases, Male, +13 more
- Locations
-
- University of California, San Francisco San Francisco, California, United States
- University of Chicago Evergreen Park, Illinois, United States
- University of Michigan Ann Arbor, Michigan, United States